Vimarsana
Biggest News Aggregation in the World

Hanlim Pharm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hanlim Pharm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hanlim Pharm Today - Breaking & Trending Today

Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 - Vimarsana News

Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034

/PRNewswire/ -- DelveInsight's Giant-Cell Arteritis Market Insights report includes a comprehensive understanding of current treatment practices, giant-cell...

Musculoskeletal Pain Market Set to Observe Remunerative Growth During the Study Period (2019-2032) | DelveInsight - Vimarsana News

Musculoskeletal Pain Market Set to Observe Remunerative Growth During the Study Period (2019-2032) | DelveInsight

New York, USA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Musculoskeletal Pain Market Set to Observe Remunerative Growth During the Study Period (2019-2032) | DelveInsight The emergence of new products in the pipeline

New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles - Vimarsana News

New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles

/PRNewswire/ -- DelveInsight's 'Rheumatoid Arthritis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

Drug patent expiry in 2021: Opportunities and challenges in the Korean market - Vimarsana News

Drug patent expiry in 2021: Opportunities and challenges in the Korean market

Drug patent expiry in 2021: Opportunities and challenges in the Korean market Min Son of Hanol IP & Law looks ahead at the key deadlines in the South Korean drug patent market for 2021 Sponsored by January 12 2021 With each new year, pharmaceutical companies are faced with the loss of exclusivity that accompanies the expiration of their patents, and by the same token, drug manufacturers are also afforded new opportunities and challenges due to the entry of generic competition. In South Korea, as many as 62 patents for 158 pharmaceuti...